Parada, et al's discovery of this autocrine signaling axis’ involvement in NF1-derived MPNST cells provides an exciting opportunity to explore novel therapies targeting CXCL12/CXCR4 autocrine signaling to treat MPNST patients [6]. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.